Intropin Side Effects
Generic name: dopamine
Medically reviewed by Drugs.com. Last updated on Jul 28, 2021.
Note: This document contains side effect information about dopamine. Some of the dosage forms listed on this page may not apply to the brand name Intropin.
For the Consumer
Applies to dopamine: parenteral injection concentrate for iv infusion, parenteral injection for iv infusion
- Phentolamine is the local antidote for peripheral ischemia resulting from extravasation of dopamine.115 116
- Phentolamine should be given as soon as possible after extravasation is noted.115 116
- Infiltrate the affected area (using a syringe with a fine hypodermic needle) liberally throughout as soon as possible with 10–15 mL of 0.9% sodium chloride injection containing 5–10 mg of phentolamine mesylate (an α-adrenergic blocking agent) to prevent sloughing and necrosis in ischemic areas.115 116
- In children, phentolamine mesylate doses of 0.1–0.2 mg/kg (maximum: 10 mg per dose) may be infiltrated.116
- Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours.115 116
Side effects include:
Dopamine (the active ingredient contained in Intropin) may cause cardiac conduction abnormalities (e.g., ventricular arrhythmia, atrial fibrillation, widened QRS complex, ectopic heartbeats), tachycardia, angina, palpitation, bradycardia, vasoconstriction, hypotension, hypertension, dyspnea, nausea, vomiting, headache, anxiety, azotemia, piloerection, and gangrene of the extremities.
For Healthcare Professionals
Applies to dopamine: intravenous solution
Common (1% to 10%): Ectopic beats, tachycardia, anginal pain, palpitation, hypotension, vasoconstriction
Uncommon (0.1% to 1%): Aberrant ventricular conduction/ventricular arrhythmia, bradycardia, widened QRS complex, hypertension
Frequency not reported: Gangrene of the feet/extremities, peripheral cyanosis, fatal ventricular arrhythmias, atrial fibrillation, cardiac conduction abnormalities[Ref]
Gangrene of the feet occurred in patients with preexisting vascular disorders and/or at doses of at least 10 to 14 mcg/kg/min given for prolonged periods of time.
Ventricular arrhythmias occurred at very high doses.[Ref]
Common (1% to 10%): Nausea, vomiting[Ref]
Common (1% to 10%): Headache[Ref]
Common (1% to 10%): Dyspnea[Ref]
Very rare (less than 0.01%): Gangrene
Frequency not reported: Piloerection[Ref]
Frequency not reported: Necrosis, tissue sloughing, local ischemia and vasoconstriction[Ref]
Necrosis and tissue sloughing may be caused by extravasation of this drug.[Ref]
Frequency not reported: Anxiety[Ref]
Frequency not reported: Azotemia[Ref]
Frequency not reported: Mydriasis[Ref]
Frequency not reported: Hypovolemia[Ref]
Frequently asked questions
More about Intropin (dopamine)
Related treatment guides
1. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE.
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Some side effects may not be reported. You may report them to the FDA.